Difference between revisions of "Hepatocellular carcinoma - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
||
| Line 26: | Line 26: | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
| − | |[ | + | |[https://ascopubs.org/doi/full/10.1200/jco.2012.45.8372 Cheng et al. 2013 (SUN 1170)] |
| style="background-color:#1a9851" |Phase III (E) | | style="background-color:#1a9851" |Phase III (E) | ||
|[[Hepatocellular_carcinoma#Sorafenib_monotherapy|Sorafenib]] | |[[Hepatocellular_carcinoma#Sorafenib_monotherapy|Sorafenib]] | ||
| Line 38: | Line 38: | ||
'''42-day cycles''' | '''42-day cycles''' | ||
===References=== | ===References=== | ||
| − | # Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. [ | + | # Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. [https://ascopubs.org/doi/full/10.1200/JCO.2008.20.9908 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702235/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19470923 PubMed] |
| − | # '''SUN 1170:''' Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. Epub 2013 Sep 30. [ | + | # '''SUN 1170:''' Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. Epub 2013 Sep 30. [https://ascopubs.org/doi/full/10.1200/jco.2012.45.8372 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24081937 PubMed] |
==Tamoxifen monotherapy {{#subobject:52e6cb|Regimen=1}}== | ==Tamoxifen monotherapy {{#subobject:52e6cb|Regimen=1}}== | ||
| Line 63: | Line 63: | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
|- | |- | ||
| − | |[ | + | |[https://ascopubs.org/doi/full/10.1200/JCO.2005.05.470 Barbare et al. 2005 (FFCD 9403)] |
| style="background-color:#1a9851" |Phase III (E) | | style="background-color:#1a9851" |Phase III (E) | ||
|[[Hepatocellular_carcinoma#Best_supportive_care|Best supportive care]] | |[[Hepatocellular_carcinoma#Best_supportive_care|Best supportive care]] | ||
| Line 84: | Line 84: | ||
# '''CLIP-1:''' Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)01259-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9800740 PubMed] | # '''CLIP-1:''' Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)01259-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9800740 PubMed] | ||
# Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002 Nov;36(5):1221-6. [https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1053/jhep.2002.36824 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12395333 PubMed] | # Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002 Nov;36(5):1221-6. [https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1053/jhep.2002.36824 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12395333 PubMed] | ||
| − | # '''FFCD 9403:''' Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. [ | + | # '''FFCD 9403:''' Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. [https://ascopubs.org/doi/full/10.1200/JCO.2005.05.470 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15994145 PubMed] |
# Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. [https://www.nature.com/articles/6603901 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17687341 PubMed] | # Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. [https://www.nature.com/articles/6603901 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17687341 PubMed] | ||
# '''FFCD 9402:''' Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. [https://www.ejcancer.com/article/S0959-8049(08)00008-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18242076 PubMed] | # '''FFCD 9402:''' Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. [https://www.ejcancer.com/article/S0959-8049(08)00008-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18242076 PubMed] | ||
Revision as of 14:58, 23 June 2019
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main HCC page for current regimens.
4 regimens on this page
7 variants on this page
|
First-line therapy
Sunitinib monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Zhu et al. 2009 | Phase II | ||
| Cheng et al. 2013 (SUN 1170) | Phase III (E) | Sorafenib | Inferior OS |
Early trial termination of the phase III trial occurred for futility and safety reasons; sunitinib treated patients demonstrated inferior OS and more frequent and severe toxicities. Dosing preserved for historical context.
Chemotherapy
- Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 28
- Dose can be reduced to 25 and 12.5 mg once per day depending on toxicity
42-day cycles
References
- Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. link to original article contains verified protocol link to PMC article PubMed
- SUN 1170: Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. Epub 2013 Sep 30. link to original article PubMed
Tamoxifen monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| CLIP Group (CLIP-1) | Phase III (E) | Best supportive care | Seems not superior |
| Chow et al. 2002 | Phase III (E) | Placebo | Seems to have inferior OS |
| Barbare et al. 2005 (FFCD 9403) | Phase III (E) | Best supportive care | Seems not superior |
| Verset et al. 2007 | Phase III (C) | Octreotide LAR & Tamoxifen | Seems not superior |
| Doffoël et al. 2008 (FFCD 9402) | Phase III (C) | TACE & Tamoxifen | Seems not superior |
Chemotherapy
References
- CLIP-1: Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. link to original article PubMed
- Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002 Nov;36(5):1221-6. link to original article PubMed
- FFCD 9403: Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. link to original article PubMed
- Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. link to original article link to PMC article PubMed
- FFCD 9402: Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. link to original article PubMed